Satellos Bioscience Inc. Common Stock (MSLE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Satellos Bioscience Inc. Common Stock (MSLE) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.83 Million) by net assets ($59.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Satellos Bioscience Inc. Common Stock for the company's overall valuation and market capitalisation.
Satellos Bioscience Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Satellos Bioscience Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Satellos Bioscience Inc. Common Stock ranked by their cash flow conversion efficiency. See MSLE debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
0.062x |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
0.117x |
|
Intops Co. Ltd
KQ:049070
|
0.011x |
|
Kimteks Poliuretan Sanayi ve Ticaret AS
IS:KMPUR
|
0.157x |
|
Studsvik AB
ST:SVIK
|
0.140x |
|
NORTHERN OCEAN LTD.
F:4JO
|
-0.091x |
|
Nucleus Software Exports Limited
NSE:NUCLEUS
|
0.137x |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc. Common Stock (2007–2025)
The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc. Common Stock from 2007 to 2025. View today's stock price for Satellos Bioscience Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.78 Million | $-23.60 Million | -0.849x | -130.76% |
| 2024-12-31 | $47.28 Million | $-17.40 Million | -0.368x | -3.82% |
| 2023-12-31 | $40.67 Million | $-14.42 Million | -0.354x | +79.12% |
| 2022-12-31 | $3.34 Million | $-5.66 Million | -1.698x | -253.57% |
| 2021-12-31 | $8.22 Million | $-3.95 Million | -0.480x | -105.32% |
| 2020-12-31 | $-184.25K | $-1.66 Million | 9.030x | +366.60% |
| 2019-12-31 | $678.67K | $-2.30 Million | -3.387x | -291.50% |
| 2018-12-31 | $-622.52K | $-1.10 Million | 1.769x | +407.07% |
| 2016-12-31 | $2.33 Million | $-1.34 Million | -0.576x | +29.65% |
| 2015-12-31 | $3.77 Million | $-3.09 Million | -0.819x | -59.16% |
| 2014-12-31 | $5.26 Million | $-2.71 Million | -0.514x | +82.25% |
| 2013-12-31 | $1.23 Million | $-3.57 Million | -2.898x | -115.11% |
| 2012-12-31 | $2.05 Million | $-2.77 Million | -1.347x | -87.28% |
| 2011-12-31 | $2.69 Million | $-1.93 Million | -0.719x | +35.67% |
| 2010-12-31 | $2.40 Million | $-2.68 Million | -1.118x | -126.79% |
| 2009-12-31 | $4.31 Million | $-2.12 Million | -0.493x | +78.84% |
| 2008-12-31 | $894.78K | $-2.08 Million | -2.330x | -48.35% |
| 2007-12-31 | $2.49 Million | $-3.90 Million | -1.570x | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more